Enrichment Factors for Clinical Trials in Mild-to-Moderate Alzheimer’s Disease

Authors

• Clive Ballard, University of Exeter Medical School
• Alireza Atri, Banner Sun Health Research Institute
• Neli Boneva, Lundbeck A/S
• Jeffrey L. Cummings, University of Nevada, Las VegasFollow
• Lutz Frolich, University of Heidelberg
• Jose Luis Molinuevo, Barcelona Brain Research Center
• Pierre N. Tariot, Cleveland Clinic Lou Ruvo Center for Brain Health
• Lars Lau Raket, Lundbeck A/S

Document Type

Article

Publication Date

1-1-2019

Publication Title

Alzheimer’s and Dementia

Volume

5

First page number:

164

Last page number:

174

Abstract

Heterogeneity of outcomes in Alzheimer’s disease (AD) clinical trials necessitates large sample sizes and contributes to study failures. This analysis determined whether mild-to-moderate AD populations could be enriched for cognitive decline based on apolipoprotein (APOE)ε4 genotype, family history of AD, and amyloid abnormalities.

Keywords

Alzheimer’s disease; Clinical trial; Enrichment; Power; Biomarkers

Disciplines

Medicine and Health Sciences

File Format

pdf

File Size

585 KB

Language

English

Rights

IN COPYRIGHT. For more information about this rights statement, please visit http://rightsstatements.org/vocab/InC/1.0/

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Repository Citation

Ballard, C., Atri, A., Boneva, N., Cummings, J. L., Frolich, L., Molinuevo, J., Tariot, P. N., Raket, L. (2019). Enrichment Factors for Clinical Trials in Mild-to-Moderate Alzheimer’s Disease. Alzheimer’s and Dementia, 5 164-174.
http://dx.doi.org/10.1016/j.trci.2019.04.001